Objective: To investigate the cost-effectiveness of the first patient self-paying pharmacist-assisted warfarin monitoring (PAWM) program in Taiwan. Design: A Markov model with a 1-month cycle length and a 20-year time horizon was employed in this study. The model is composed of the following eight states: three no-event states (i.e. 'subtherapeutic,' 'within therapeutic' and 'supratherapeutic' states), two serious adverse events (AEs) (i.e. bleeding and thromboembolism), two sequelae states and death. The likelihood of events, costs and utilities were derived from local databases and literature, if applicable. This study was conducted with a payer's perspective and all costs were discounted with a rate of 3%. Setting: A pharmacist-led clinic. Participants: A hypothetical cohort of 10 000 participants. Intervention(s): PAWM versus usual care. Main outcome measure(s): Average quality-adjusted life-years (QALYs) gained and cost increments per patient, and incremental cost-effectiveness ratios (ICERs). Results: The PAWM program resulted in an average of 0.13 QALYs gained and a cost increment of NT$53 850 (US$1683) per patient. As the ICER (NT$410 749 [US$12 836]) was less than the gross domestic product per capita (NT$631 142 [US$19 723]), the PAWM was considered to be very costeffective. The sensitivity analyses suggested that our result was robust and that the PAWM program had an 86% probability of being very cost-effective. Conclusions: Even if the costs saved from avoiding AEs were thought to be minimal due to the low-medical expenditures in Taiwan, the PAWM program was demonstrated to be economical. According to our findings, the policymakers should consider reimbursing such a service.
Introduction
Warfarin is a widely prescribed oral anticoagulant and has been used for decades to prevent primary or secondary thromboembolic (TE) events in patients with atrial fibrillation (AF), vein thromboembolism and valvular disease [1] . The therapeutic window of warfarin is narrow and varies across different indications. Inappropriate dosing and poorly maintained therapeutic intensity may lead to serious adverse outcomes, such as major bleeding and TE events, which can sometimes be fatal [1] .
Owing to the high risk/benefit profile of warfarin, individualized anticoagulation therapy management plays a key role in optimizing the effectiveness and safety of warfarin therapy [2] . Many published studies have shown that the implementation of pharmacist-assisted warfarin monitoring (PAWM) have resulted in better international normalized ratio (INR) control and the reduction of major bleeding/ TE events [3] . Moreover, such services have been demonstrated to be cost-effective in many Western countries [4] . However, studies evaluating the cost-effectiveness of the PAWM program in Asia remained scarce [5, 6] .
Compared to other countries, Taiwan is unique in its universal coverage and global budget system, which keeps the medical costs low. Under the National Health Insurance (NHI) program in Taiwan, patients are free to choose their providers, including specialists, and pay only a limited amount (approximately US$15) for an outpatient visit. Whether or not the PAWM program is still cost-effective under the Taiwan's low-medical cost system remains unknown. Currently, the pharmacist-led anticoagulation clinic (AC) directly charges patients a certain amount of fees in order to compensate the operating costs of the hospital since such service has not yet been reimbursed by the NHI. We aimed to assess whether it would be economical for the NHI system to reimburse such service in the future. Therefore, we conducted an analysis to evaluate the cost-effectiveness of the first patient self-paying PAWM program established in 2012 at the National Taiwan University Hospital (NTUH).
Methods

Overview
A Markov model modified from previous studies was employed in the hypothetical cohort to capture the cost-effectiveness of the PAWM program implemented at the NTUH (Fig. 1) [5, 7, 8] . The input parameters are listed in Table 1 . The input parameters, including likelihood of events, costs and utilities, were derived from the NTUH database, the Taiwan National Health Insurance Research Database (NHIRD), and studies in Taiwan, if applicable. The NTUH database contains electronic medical records of patients receiving medical care at the NTUH, including information on the date of encounter, diagnoses, prescription records and lab test results. The NTUH database, however, does not contain details on medical costs. Therefore, additional information on the costs of medical encounters or procedures was derived from the NHIRD. All of the analyses were performed with the payer's perspective (i.e. National Health Insurance Administration). The study was approved by the Institutional Review Board of the NTUH (No. 201406035RINA).
Markov model
A 1-month cycle length was applied in our model based on the average PAWM visit interval at the NTUH. Patients entered the Markov model at the age of 60, and the time horizon of the study was 20 years. There are eight different states in the Markov model (see Fig.  1 ). Patients entered the Markov model by either participating in the PAWM program or receiving usual care (UC). The PAWM program was considered to be an additional service to UC in the model according to the current care pattern of the PAWM program at the NTUH [21] .
In the Markov model, patients were assumed to begin in noevent states. Unlike the model proposed in the previous studies [5, 7] , to best reflect the effect of the INR management of the PAWM program at the NTUH, this study divided the no-event states into 'supratherapeutic,' 'subtherapeutic' and 'within therapeutic' states, under the assumption that the 'supratherapeutic' and 'subtherapeutic' states are associated with an increased risk of major bleeding and TE events. In our study, 'subtherapeutic,' 'supratherapeutic' and 'within therapeutic' states were defined as INR values below 1.5, within 1.5-3.0, and above 3.0, respectively. The cutoff point of INR values was determined based on the warfarin dosing algorithm in Taiwan [22] .
After entering the hypothetical cohort, the patients remained event free or had warfarin-associated adverse events (AEs), namely major bleeding or TE. While staying event free, the patients may transfer between different no-event states.
Major bleeding events included intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH) and gastrointestinal (GI). Major TE events included ischemic stroke/transient ischemic attack (TIA), deep vein thrombosis (DVT) and pulmonary embolism (PE).
After experiencing a warfarin-associated AE, patients may have sequelae or go back to a no-event state within the therapeutic range based on the assumption that the patients' INR is under control upon discharge after intensive monitoring in the hospital. Once the patients developed sequelae, they were not allowed to go back to the no-event states. Only patients with ICH/SAH and ischemic stroke/TIA were considered at risk of developing such long-term sequelae in our model based on their clinical features [23] . This model also accounts for the risk of mortality at all states, and the background death rates at noevent states were considered identical for all INR ranges.
Likelihood of events
The INR transition probabilities were obtained from a propensity score-matched cohort at the NTUH (Supplementary Tables 1 and  2) , which was conducted to compare the clinical effectiveness of the PAWM program versus UC. The concept of monthly cross-section records and Rosendaal linear interpolations were applied to the time in therapeutic range calculation [2, 24] . Due to the complexity of defining the probability of developing warfarin-associated AEs at different INR states and the potential detection bias of hospital databases, we adapted the probability of developing major TE and major bleeding events from Western literature, where the probabilities were pooled data from several sources [9] . In addition, the probabilities of developing major bleeding were modified by a hazard ratio retrieved from literature reflecting the higher bleeding incidence in Asians compared to Caucasians [10] .
The proportions of stroke/TIA in major TE and ICH/SAH in major bleeding were adapted from the results of the propensity score-matched cohort. For the probability of developing permanent sequelae from stroke/TIA and ICH/SAH, we adapted the probability from Taiwanese and Western literature, respectively [9, 11] .
The background death rate of no-event states was modified from the age-specific probability of death of the Taiwanese population [15] . The background death rate of no-event states in our model accounted for the mortality risk due to reasons other than developing major bleeding and TE, which generally are not (directly) related to warfarin. As AF represents over 60% of the indications in our study population, the age-specific death probabilities were modified by a factor obtained from literature indicating a higher probability of death in AF patients [16] .
Probabilities of death from major TE and major bleeding events were adapted from Taiwanese literature [11] [12] [13] [14] . The probabilities of death from sequelae were assumed by multiplying the age-specific death probability in no-event states by a certain death risk ratio as lacking such data in the Taiwanese population. The predicted range of the death risk ratios were applied from Western literature [9] . Probabilities derived from literature were converted to 1-month probabilities with a standard equation, if needed [8] .
Costs
Only direct medical costs were taken into account, including the costs of the INR testing, the PAWM service, major TE and bleeding events and sequelae. The costs of warfarin and physician visits were neglected because these costs should be comparable in both the PAWM and UC groups according to the assumption that the PAWM program was an additional service to UC at the NTUH [21] . For comparing the costs in our study with those in other countries, an exchange rate of US$1 ≈ NT$32 can be used for converting New Taiwanese dollars (NT$) into US$.
The costs of the INR tests and PAWM services were derived from the NTUH data based on the average number of INR tests and time of PAWM services per month. The average number of INR tests per month was 1.54 (95% confidence interval [CI] 1.43-1.64) and 0.59 (95% CI 0.54-0.63) in the PAWM group and UC group, respectively. The costs of the PAWM service were categorized into the cost of the first PAWM visit and the subsequent PAWM visits since the pharmacists usually spent more time with the patients during the first visit [25] .
The costs of ischemic stroke/TIA, ICH/SAH and sequelae were retrieved from Taiwanese literature weighted with the frequency of each event subtype [17] . Due to a lack of statistics from literature, the costs of DVT/PE and GI bleeding were calculated based on the claims information in the NHIRD. All of the costs were presented in NT$ and adjusted to the value in 2012 according to the medical component of the consumer price index in Taiwan [26] .
Utilities
All of the utility values were obtained from literature. The utilities of stroke/TIA, ICH/SAH events and related sequelae states were obtained from Taiwanese literature [18] , while the other utilities were retrieved from studies conducted in other countries [5, 7, 19] .
Base-case analysis
The base-case analysis was carried out with a hypothetical cohort of 10 000 patients receiving warfarin therapy. The initial distribution of the patients in three different no-event states was based on the distribution of the patients' initial INR values in the UC group at When computed in the Markov model, the INR transitions probabilities were multiplied by the probability of the remaining event free in the corresponding different no-event states (i.e. 1 minus the probability of developing major TE/major bleeding events and age-specific probability of death). The original upper limit was 0.8566. However, it was amended to 0.6806 to prevent the sum of the probabilities coming out from supratherapeutic state more than 1 in the PSA.
c Only used in lifetime horizon scenario sensitivity analysis.
the NTUH. The same distribution was used for both intervention alternatives in our analysis, considering that the Markov model was thought to simulate the cost-effectiveness on the same population with and without the PAWM program. The discount rate was set as 3% with a range of 0-6% based on the cost-effectiveness analysis guideline of the Health Technology Assessment body in Taiwan [20] . The results were presented as incremental cost-effectiveness ratios (ICERs) per quality-adjusted life-year (QALY) and per life year (LY). As there is no consensus regarding the willingness-to-pay (WTP) per QALY gained in Taiwan, the widely used World Health Organization recommendation was applied to define the cost-effectiveness of our results [27] . If the ICER per QALY is less than GDP per capita, then the intervention is considered to be 'very cost-effective'; if the ICER per QALY is between one and three times GDP per capita, then the intervention is considered to be 'cost-effective.' The GDP per capita of Taiwan in 2012 was NT$631 142 [28] .
An international internet survey with a sample size of 504 randomly selected respondents from Taiwan indicated that an estimated NT$ 2.1 million per QALY gained (roughly US$69 000) might serve as the WTP threshold in Taiwan. Such a number is higher than 3 GDP per QALY gained in Taiwan. Therefore, we assume that 1-3 per QALY gained may serve as a conservative and reasonable reference [29] .
Sensitivity analyses
One-way sensitivity analyses were performed with the upper and lower limits of each parameter. The upper and lower limits of each parameter were simply adapted if indicated in literature. Otherwise, a 95% CI (i.e. ± 25% variation of a parameter) was applied.
A probabilistic sensitivity analysis (PSA) was also performed to test the robustness of the analysis. In the PSA, 1000 Monte Carlo simulations (MCSs) were executed. The values of each parameter were randomly drawn from the plausible ranges, and the estimated ICERs were calculated for each simulation. We have applied the triangle distribution for each variable in the MCSs as the data we obtained are mostly point estimate with either 95% confidence interval or ±25% variation of a parameter. As we were not able to test the original distribution of every parameter included, we have also conducted a supplementary analysis to check the robustness of our results, with gamma distribution for costs, beta distribution for utilities and event types, and normal distribution for the other parameters.
Additionally, several scenario sensitivity analyses were conducted to examine the results in the 'worst-case' scenarios. First, we altered the initial distributions of patients in no-event states, including patients all starting in 'supratherapeutic,' 'within therapeutic' or 'subtherapeutic' states. Second, a lifetime horizon was applied to the model instead of the 20-year horizon. This scenario was based on the theory that warfarin use may also provide clinical benefits in the elderly population, who are usually more vulnerable if their INR is not well controlled [30, 31] .
All of the analyses were performed using SAS 9.4 (SAS Institute, Cary, NC), Microsoft ® Excel (Microsoft Corp., Redmond, WA) and
Crystal Ball (Oracle Corp., Redwood Shores, CA).
Results
Base-case analysis
From the payer's perspective ( One-way sensitivity analysis
In Fig. 2 , a tornado plot illustrates the results of the one-way sensitivity analysis. The uncertainty of the probability of pushing patients from the 'subtherapeutic' state back to the 'within therapeutic' state in the UC group had the most drastic effect on the results in the model. The PAWM program would become less cost-effective if the UC group had better control on the INR values. The effect scale of the PAWM program's monthly cost ranked second in the one-way sensitivity analysis, with an increase in the ICER as the fees of the 
Probabilistic sensitivity analysis
In the probability sensitivity analysis (Figs 3 and 4) , the PAWM program had an 86% probability of being very cost-effective with a WTP of GDP per capita. If raising the WTP to three GDP per capita, then the PAWM program was considered to be 100% cost-effective. Results of the supplementary analyses were consistent with the original MCS, which suggested that the PAWM have an 84% probability to be very cost-effective at a WTP of GDP per capita.
Scenario sensitivity analyses
The results of the scenario sensitivity analyses also suggested that the PAWM program was very cost-effective compared to UC (Table 2) . First, changing the initial distributions of patients in noevent states resulted in an ICER per QALY gained ranging from NT $403 854 to NT$439 434. A higher ICER would be observed when a higher percentage of the patients started from the 'within therapeutic' range state, indicating that the PAWM program would be less cost-effective if patients' INR was well controlled under UC. Second, conducting the analysis with a lifetime horizon led to an even greater QALYs gained and a smaller ICER.
Discussion
To our knowledge, this is the first study that takes into account different risks of AEs under particular INR ranges while assessing the cost-effectiveness of the PAWM program. Our study demonstrated that the PAWM program was very cost-effective compared to UC, even under the global budget system in Taiwan where medical costs were highly controlled. This finding was similar to the results from previous studies, including one conducted in the United States, which has a free healthcare market [4] [5] [6] . These combined results suggested that the PAWM program is a cost-effective service across a variety of types of healthcare systems. While our study specifically evaluate the cost-effectiveness of a pharmacist-led AC (i.e. PAWM), ACs in other studies may be run by the physicians or other health professions. Therefore, the term AC is applied in the following discussion rather than PAWM to address the difference. You et al. found the implementation of a physician-run AC to be cost-effective compared to UC in a 10-year horizon [6] . In You's study, the AC served as a substitute for UC, and it was expected to lower the AEs by 51% and reduce the costs by 29% compared to UC. The AC was initially hosted by physicians, and the author suggested that the costs saved may be even greater if pharmacists fully take over the service in the future due to the lower salary of pharmacists [6] . Our model assessed the cost-effectiveness of the pharmacist-run AC: PAWM program as an additional service. The PAWM program is expected to be even more cost-effective if this service is able to reduce or replace certain levels of physician services (e.g. reduce physician visits).
Utilizing the data from the SPORTIF V trial, Sullivan et al. found that the AC was cost-effective in a 10-year horizon from a societal perspective. It was not clear in Sullivan's study whether the AC was run mainly by physicians or pharmacists. Nevertheless, both physician and pharmacist labor costs were included in the costs of clinic visits. The AC increased QALYs by 0.057 (95% CI 0-0.36) and reduced costs by US$2100 (NT$67 200) per person, which was the dominant strategy compared to UC [4] . The main cost saving in the AC group was derived primarily from the saving of AEs in Sullivan's study [4] . Given the high medical costs in the United States, our study demonstrated that the AC could still be cost-effective even under a low-medical cost system like the system in Taiwan.
The one-way sensitivity analysis suggested that the effect size of PAWM and the fees of the PAWM service are relative influential factors, although none of these factors appeared to alter our study results. For example, four of the top five parameters that contributed the most to the variances in the model were INR control related (Fig. 2) , and these four parameters contributed to approximately half (45%) of the variances in the model. This suggested that the benefit of the PAWM services mostly came from the effect of INR control, which can be largely enhanced by pharmacists. Therefore, policymakers may consider paying for such a pharmacy service.
In recent years, the use of warfarin has been substituted gradually by novel oral anticoagulants (NOACs), namely direct factor Xa inhibitors (e.g. rivaroxaban, apixaban and edoxaban) and direct thrombin inhibitors (e.g. dabigatran). Some studies suggested that the use of NOACs may be more cost-effective as frequent INR monitoring are not required [32, 33] . Although being potentially cost-effective, NOACs may not be listed in the formulary in some places due to the high cost. Therefore, the use of warfarin remains relevant as warfarin possesses a broader indication spectrum compared to NOACs. For example, NOACs are not suitable for patients with mechanical valves nor patients who are renal impaired. Additionally, a relatively cheap anti-dote for warfarin, vitamin K, is commercially available [1, 2] . Given the reasons above, we believe that warfarin will still have a role in anticoagulation therapy, and thus the PAWM will still has its importance in terms of the anticoagulation therapy management.
Finally, while our study was conducted from the payer's perspective, we believed that the PAWM will be even more cost-effective from the societal perspective. Several studies suggested that stroke may impose a greater burden if taking both the medical costs and societal costs into account [34, 35] . Moreover, some studies indicated that stroke might also cause financial, physical and psychological burden to the caregivers [36, 37] . In summary, the amount of the costs saved and the potential benefits with the PAWM implementation are expected to be enlarged if evaluated with the societal perspective.
There are several strengths of our study. First, we incorporated local data to demonstrate the clinical effectiveness of the PAWM program. Prior studies have applied data from meta-analyses or studies conducted in other countries to obtain data for warfarinassociated AEs [4] [5] [6] . In contrast, the clinical benefits in our study were derived from the data of the NTUH, which was considered to be a more suitable source for representing the true effect scale of the PAWM program in Taiwan [21, 25] . Second, our model is the first model that incorporated the transitions of the INR over time, reflecting the higher risks of developing warfarin-associated AEs with an INR value out of the therapeutic range. Such a model design not only reflected the clinical situation better than the single no-event state design, but also provided future researchers a reasonable and time-saving method to conduct a cost-effectiveness analysis on similar topics when a long-term data collection of warfarin-associated AEs is not feasible. Lastly, a significant number of sensitivity analyses were performed to test the robustness of the results. It was commendable that our findings supported the PAWM program to be very cost-effective; even the costs averted from reducing the warfarin-associated AEs were thought to be relatively small compared to Western countries [4] .
Several key assumptions and limitations of our study should be addressed. First, some input parameters were retrieved from Western literature or assumed. However, these parameters did not appear to have any significant influence on the results in the oneway sensitivity analysis. Furthermore, the model assumed that all of the patients in the PAWM group received the additional service until they were dead, but it was possible that the patients may have discontinued the PAWM service early. Finally, whether or not the results could be extrapolated to other Asian countries remained unclear. Most of the parameters in our study were derived from Taiwanese databases, where the ethnicity is relatively homogeneous, but it is unclear whether there is any inherent difference among different Asian subgroups in terms of warfarin sensitivity and health utility values. It should also be noted that how health care is provided in each country may alter the results as the quality of the PAWM service is an influential factor in the model. In addition, medical costs in Taiwan cannot simply be applied in other countries, especially because Taiwan has a single payer health system, in which the costs are highly constrained. However, our model still provides a good framework for further researchers to evaluate the costeffectiveness of the PAWM program in different countries.
In conclusion, our findings provide the evidence on the costeffectiveness of the PAWM program, and policymakers should consider reimbursing such a service.
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